FDA Advisory Committee votes in favor of Valtrex for the reduction of genital herpes transmission
FDA Advisory Committee votes in favor of Valtrex for the reduction of genital herpes transmissionRESEARCH TRIANGLE PARK, N.C., May 14, 2003 -- GlaxoSmithKline announced that an FDA Advisory Committee unanimously (13-0) recommended the approval of once-daily suppressive therapy with Valtrex (valacyclovir HCl) for the reduction of transmission of genital herpes in otherwise healthy, heterosexual, monogamous couples.
The committee advised the FDA that suppressive therapy with Valtrex, in addition to safer sex counseling and use of condoms, was shown to be safe and effective in reducing transmission of genital herpes in heterosexual, otherwise healthy individuals. The committee's favorable recommendation will be considered by the FDA in its review of the supplemental new drug application (sNDA) GSK has submitted for Valtrex.
"We are extremely encouraged by this recommendation which recognizes the need for an important new therapeutic approach addressing a major concern of patients: transmission of genital herpes to their partners," said Clarence L. Young, M.D., Vice President, Clinical Development and Medical Affairs, GlaxoSmithKline. "We look forward to working with the FDA to further progress this application."
The FDA is not bound by the committee's recommendation, but takes such advice into consideration when determining its decision on an application.
The study undertaken in support of the sNDA showed that once-daily suppressive therapy with Valtrex 500 mg caplets reduced transmission of symptomatic genital herpes (signs or symptoms of an outbreak confirmed with a lab test) by 75 percent versus placebo (0.5 percent vs 2.2 percent) in 1484 healthy, heterosexual, monogamous couples. In addition, suppressive therapy with Valtrex reduced the overall acquisition of the virus (determined by a positive lab test) by 48 percent versus placebo (1.9 percent vs. 3.6 percent). Throughout the study, all couples were counseled on safer sex practices at all study visits and encouraged to use condoms; condoms were offered free of charge. The principles of safer sex practices were (1) to avoid sexual contact when the source partner had any symptoms of genital herpes and (2) consistent and correct use of condoms during all sexual contacts.
In this study, Valtrex was generally well-tolerated. The most commonly reported side effects in the study were headache (Valtrex 29%, placebo 26%), nasopharyngitis (Valtrex 16%, placebo 15%), upper respiratory infection (Valtrex 9%, placebo 10%), sore throat (Valtrex 8%, placebo 7%) and diarrhea (Valtrex 8%, placebo 7%). The effect of Valtrex on transmission of genital herpes has not been studied among individuals with multiple partners, non- heterosexual couples, couples not counseled on using safer sex practices, nor in people with HIV. The effect of Valtrex on transmission has not been studied beyond eight months.
Valtrex is currently indicated for the treatment or suppression of genital herpes in otherwise healthy individuals and for the suppression of recurrent genital herpes in HIV-infected individuals. Adverse events reported with Valtrex include headache, nausea, abdominal pain, fatigue and rash. Valtrex is intended for adults with normal immune systems or HIV-infected adults with CD4+ counts > or = 100cells/uL. No data are available on the efficacy of treatment with Valtrex of more than one year's duration for suppressive therapy in healthy patients (six months in HIV-infected patients), or started more than 24 hours after the onset of signs and symptoms for episodic therapy. To avoid a potentially serious complication, patients should tell their doctor if their immune system is not normal because of advanced HIV disease, bone marrow or kidney transplant.
There is no cure for the herpes virus and even with treatment it may be possible to spread herpes to others.
For more information on Valtrex, including full prescribing information, visit www.Valtrex.com or call 1-888-825-5249.
Source: GlaxoSmithKline www.gsk.com
Posted: May 2003